Population pharmacokinetics and antimalarial pharmacodynamics of piperaquine in patients with Plasmodium vivax Malaria in Thailand

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 8, 2014, Pages

  Tarning, J ^a,b   Thana, P ^a   Phyo, A P ^a   Lwin, K M ^a   Hanpithakpong, W ^a   Ashley, E A ^a,b   Day, N P J ^a,b   Nosten, F ^a,b   White, N J ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84906890551     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2014.29     Document Type: Article

References (33)

1. Price, R.N., Tjitra, E., Guerra, C.A., Yeung, S., White, N.J. & Anstey, N.M. Vivax malaria: neglected and not benign. Am. J. Trop. Med. Hyg. 77, 79-87 (2007).
2. Guerra, C.A. et al. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med. 5, e38 (2008).
3. Guerra, C.A. et al. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl. Trop. Dis. 4, e774 (2010).
4. Anstey, N.M., Russell, B., Yeo, T.W. & Price, R.N. The pathophysiology of vivax malaria. Trends Parasitol. 25, 220-227 (2009).
5. Poespoprodjo, J.R. et al. Vivax malaria: a major cause of morbidity in early infancy. Clin. Infect. Dis. 48, 1704-1712 (2009).
6. Nosten, F. et al. Effects of Plasmodium vivax malaria in pregnancy. Lancet 354, 546-549 (1999).
7. Collins, W.E., Jeffery, G.M. & Roberts, J.M. A retrospective examination of anemia during infection of humans with Plasmodium vivax. Am. J. Trop. Med. Hyg. 68, 410-412 (2003).
8. Rieckmann, K.H., Davis, D.R. & Hutton, D.C. Plasmodium vivax resistance to chloroquine? Lancet 2, 1183-1184 (1989).
9. Baird, J.K. Chloroquine resistance in Plasmodium vivax. Antimicrob. Agents Chemother. 48, 4075-4083 (2004).
10. WHO. World Health Organization Guidelines for the Treatment of Malaria. (WHO, Geneva, Switzerland 2010).
11. Zwang, J. et al. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS ONE 4, e6358 (2009).
12. Douglas, N.M., Anstey, N.M., Angus, B.J., Nosten, F. & Price, R.N. Artemisinin combination therapy for vivax malaria. Lancet Infect. Dis. 10, 405-416 (2010).
13. Ratcliff, A. et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 369, 757-765 (2007).
14. Karunajeewa, H.A. et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N. Engl. J. Med. 359, 2545-2557 (2008).
15. Tarning, J. et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin. Pharmacol. Ther. 91, 497-505 (2012).
16. Phyo, A.P. et al. Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin. Infect. Dis. 53, 977-984 (2011).
17. Ashley, E.A. et al. Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria. Eur. J. Clin. Pharmacol. 66, 705-712 (2010).
18. Cox, E.H., Veyrat-Follet, C., Beal, S.L., Fuseau, E., Kenkare, S. & Sheiner, L.B. A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron. J. Pharmacokinet. Biopharm. 27, 625-644 (1999).
19. White, N.J. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar. J. 10, 297 (2011).
20. White, N.J. Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization. Antimicrob. Agents Chemother. 57, 5792-5807 (2013).
21. Pukrittayakamee, S. et al. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob. Agents Chemother. 44, 1680-1685 (2000).
22. Tarning, J. et al. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and non-pregnant women with uncomplicated malaria. Antimicrob. Agents Chemother. 56, 1997-2007 (2012).
23. Hung, T.Y. et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br. J. Clin. Pharmacol. 57, 253-262 (2004).
24. Tarning, J. et al. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob. Agents Chemother. 52, 1052-1061 (2008)
25. Hoglund, R.M. et al. A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Malar. J. 11, 398 (2012).
26. Holford, N.H. A size standard for pharmacokinetics. Clin. Pharmacokinet. 30, 329-332 (1996).
27. Rijken, M.J. et al. Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria. Antimicrob. Agents Chemother. 55, 5500-5506 (2011).
28. Nguyen, D.V. et al. Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam. Antimicrob. Agents Chemother. 53, 3534-3537 (2009).
29. Tarning, J. et al. Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy. Antimicrob. Agents Chemother. 56, 5764-5773 (2012).
30. Price, R.N. et al. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob. Agents Chemother. 51, 4090-4097 (2007).
31. Lindegardh, N., Annerberg, A., White, N.J. & Day, N.P. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 862, 227-236 (2008).
32. Wilkins, J.J. NONMEMory: a run management tool for NONMEM. Comput. Methods Programs Biomed. 78, 259-267 (2005).
33. Jonsson, E.N. & Karlsson, M.O. Xpose-an S-PLUS based population pharmacokinetic/ pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58, 51-64 (1999).